Pandemic blues: the global approach to COVID-related IP

As the COVID-19 pandemic reaches its two-year anniversary, the world’s battle against the virus continues. But while the world’s attention is (rightly) focused on variants, vaccines and other virus mitigation tools, there are less-reported seismic shifts in the global approach to IP among private companies and governments reacting to COVID-19.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

In conversation with...Beatriz San Martin, Arnold & Porter

13 October 2022 The scientist-turned IP specialist chats to LSIPR about why she ‘loves’ the IP sector, her views on policy and funding in science and research, and the cases she’s most proud of.

Big Pharma

Biopharma group urges fairer access to pandemic protection

21 July 2022 Global industry body launches declaration | Poorer nations could benefit from more equitable vaccine access | Proposal to be tabled among G7 and G20.

Europe

UK implored to back COVID-19 IP waiver at WTO

11 March 2021 The UK has been urged to back a proposed IP waiver related to COVID-19 treatments before the World Trade Organisation by business leaders, academics, economists and trade unions.